Abstracts tagged "cytokines"

Abstract Number: 760 • 2014 ACR/ARHP Annual Meeting
Use of Multiplex Cytokine Analysis of Dermal Blister Fluid to Assess Local Inflammatory and Immune Activity in Systemic Sclerosis
Kristina E.N. Clark¹, Henry Lopez², Xu Shiwen¹, Bahja Ahmed Abdi¹, George Martin³, Korsa Khan⁴, David J. Abraham¹, Christopher P. Denton⁵ and Richard J. Stratton¹, ¹Centre for Rheumatology and Connective Tissue Diseases, UCL Medical School, London, United Kingdom, ²Murigenics, Vallejo, CA, ³Aero Dap, Vallejo, CA, ⁴Centre for Rheumatology and Connective Tissue Diseases, UCL medical School, London, United Kingdom, ⁵Centre for Rheumatology and Connective Tissue Diseases, UCL Medical School Royal Free Campus, London, United Kingdom
Background/Purpose Clinical diversity in systemic sclerosis (SSc) suggests complex multifaceted pathogenesis involving interplay of growth factors or cytokines within the lesional microenvironment. We analysed dermal…
Abstract Number: 2991 • 2014 ACR/ARHP Annual Meeting
Anti-Ribosomal P Antibody Is a Key Autoantibody Associated with Complications of NP-SLE with High-Levels of CSF IL-8
Hidenaga Kawasumi¹, Takahisa Gono¹, Yasushi Kawaguchi¹, Yasuhiro Katsumata¹, Hisae Ichida¹, Akiko Tochimoto¹, Masanori Hanaoka¹, Yuko Okamoto¹, Sayuri Kataoka¹ and Hisashi Yamanaka², ¹Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ²Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
Background/Purpose: Complications of neuropsychiatric systemic lupus erythematosus (NP-SLE) are associated with the morbidity and mortality of patients with SLE. Although the detailed pathophysiology of NP-SLE…
Abstract Number: 1741 • 2014 ACR/ARHP Annual Meeting
Anti-TNFα Treatment Increases IL-17A+ and IL-22+ T Cells in Spondyloarthritis Regardless of Concomittant Gut Inflammation
Thomas Andersen¹, René Østgård^1,2, Bent Deleuran^1,2, Malene Hvid³ and Henning Glerup⁴, ¹Dept. of Biomedicine, Aarhus University, Aarhus, Denmark, ²Dept. of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ³Dept. of Clinical Medicine, Aarhus University, Aarhus, Denmark, ⁴Dept. of Gastroenterology, Regional Hospital of Silkeborg, Silkeborg, Denmark
Background/Purpose The pro-inflammatory Th17 associated cytokines IL-17A and IL-22 have been proposed as important mediators of the inflammation seen in spondyloarthritis (SpA) and inflammatory bowel…
Abstract Number: 754 • 2014 ACR/ARHP Annual Meeting
The Global miRNA Whole Blood Profile in Systemic Sclerosis and Its Correlation with Serum Cytokine Levels
Gloria Salazar¹, Maureen Mayes², John Hagan³, Minghua Wu¹, John D. Reveille^4,5 and Shervin Assassi¹, ¹Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, ²Internal Medicine/Rheumatology, University of TX Health Science Center -Houston, Houston, TX, ³Neurosurgery, University of Texas at Houston, Houston, TX, ⁴Internal Medicine/Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, ⁵Internal Medicine/Rheumatology, Univ of Texas Health Science Center at Houston, Houston, TX
The Global miRNA Whole Blood Profile in Systemic Sclerosis and its Correlation with Serum Cytokine LevelsBackground/Purpose: Several studies have implicated miRNAs in the pathogenesis of…
Abstract Number: 2880 • 2014 ACR/ARHP Annual Meeting
Elevated Levels of Soluble Inflammatory Mediators and Lupus-Specific Connective Tissue Disease Questionnaire Scores Discern Unaffected First Degree Relatives of Lupus Patients from Unaffected Individuals Not Related to Lupus Patients
Melissa E. Munroe¹, Kendra A. Young², Jennifer Fessler³, Dustin Fife³, Diane L. Kamen⁴, Joel M. Guthridge³, Timothy B. Niewold⁵, Michael H. Weisman⁶, Mariko L. Ishimori⁶, Daniel J. Wallace⁷, David R. Karp⁸, John B. Harley⁹, Gary S. Gilkeson⁴, Jill M. Norris² and Judith A. James^10,11, ¹Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Epidemiology, Colorado School of Public Health, Aurora, CO, ³Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, SC, ⁵Division of Rheumatology and Department of Immunology, Mayo Clinic, Rochester, MN, ⁶Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁷Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁸Rheumatic Diseases Division, UT Southwestern Medical Center, Dallas, TX, ⁹Center for Autoimmune Genomics and Etiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹⁰Clinical Arthritis and Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹¹Rheumatology, University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: Identifying populations at risk of SLE is essential to curtail inflammatory damage and select individuals for prevention trials. First-degree relatives (FDRs) of lupus patients…
Abstract Number: 1616 • 2014 ACR/ARHP Annual Meeting
Functional Profiling of PBMC from SLE Patients Versus Healthy Controls Identifies Subgroups with Disease-Associated Dysfunctional Signaling
Rachael Hawtin¹, Wouter Korver², Erik Evensen², Diane Longo², Drew Hotson², Nikil Wale², Andy Conroy², Alessandra Cesano², Barbara Mittleman², Shirley Tu², Matt Westfall², Tsung Lin³, Vik Rao⁴, Elena Peeva⁵, Stephen Benoit⁵, Martin Hodge³, James D. Clark³, Jean-Baptiste Telliez³ and Aaron R. Winkler⁴, ¹Nodality Inc., South San Francisco, CA, ²Nodality, Inc., South San Francisco, CA, ³Immunoscience, Pfizer Biotherapeutics Research and Development, Cambridge, MA, ⁴Inflammation and Remodeling, Pfizer Biotherapeutics Research and Development, Cambridge, MA, ⁵Precision Medicine, Pfizer Biotherapeutics Research and Development, Cambridge, MA
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a multi-system rheumatic disease with widely differing clinical manifestations and outcomes. Treatment is generally immunosuppressive, with no available…
Abstract Number: 651 • 2014 ACR/ARHP Annual Meeting
Inhibiting Tweak (TNF-like weak inducer of apoptosis) Signaling Improves Blood Brain Barrier Integrity and Protects from Neuronal Damage in Murine Neuropsychiatric Lupus
Jing Wen¹, Jessica Doerner¹, Ariel Stock², Jennifer Michaelson³, Linda Burkly³, Maria Gulinello² and Chaim Putterman⁴, ¹Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY, ²Albert Einstein College of Medicine, Bronx, NY, ³Biogen Idec, Cambridge, MA, ⁴The Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: While neuropsychiatric involvement in systemic lupus erythematosus (NPSLE) is relatively common and appears early, the underlying mechanisms are not fully understood. The disruption of…
Abstract Number: 2679 • 2014 ACR/ARHP Annual Meeting
Mucosal-Associated Invariant T Cell Deficiency in Systemic Lupus Erythematosus
Jeong-Hwa Kang¹, Young-Nan Cho¹, Hye Mi Jin¹, Hyun-Ju Jung¹, Sung-Ji Lee¹, Seung-Jung Kee² and Yong-Wook Park¹, ¹Rheumatology, Chonnam National University Medical School and Hospital, Gwangju, South Korea, ²Laboratory Medicine, Chonnam National University Medical School and Hospital, Gwangju, South Korea
Background/Purpose Mucosal-associated invariant T (MAIT) cells contribute to protection against certain microorganism infections and play an important role in mucosal immunity. However, the role of…
Abstract Number: 1622 • 2014 ACR/ARHP Annual Meeting
Th1 and Th2 Cytokines Are Associated with Cerebral Atrophy in Systemic Lupus Erythematosus
Mariana Postal¹, Aline T. Lapa¹, Karina de Oliveira Peliçari², Nailu A. Sinicato¹, Fernando Augusto Peres¹, Wesley Geraldo Ferreira², Roberto Marini², Lilian Costallat³, Fernando Cendes⁴ and Simone Appenzeller⁵, ¹Medicine, State University of Campinas, Campinas, Brazil, ²State University of Campinas, Campinas, Brazil, ³Medicine, State University of Campinas, Campinas, United Kingdom, ⁴Neurology, State University of Campinas, Campinas, Brazil, ⁵Medicine, Faculty of Medical Science, State University of Campinas Unicamp, São Paulo, Brazil
Background/Purpose Cerebral atrophy has been described to occur in systemic lupus erythematosus (SLE) with variable frequency. The pathophysiology of central nervous system (CNS) involvement in…
Abstract Number: 348 • 2014 ACR/ARHP Annual Meeting
Smoking Status Is Associated with Inflammatory Cytokine Profile and Disease Activity: Decreased Inflammation and Disease Improvement with Smoking Cessation?
Jeremy Sokolove¹, Harlan Sayles², Catriona Wagner³, Lauren J. Lahey¹, Geoffrey M. Thiele⁴, William H. Robinson¹, Andreas Reimold⁵, Gail S. Kerr⁶, Grant W. Cannon⁷ and Ted R. Mikuls², ¹VA Palo Alto Healthcare System and Stanford University, Palo Alto, CA, ²Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ³VA Palo Alto Heatlh Care System and Stanford University, Palo Alto, CA, ⁴Internal Medicine, Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ⁵Rheumatology, Dallas VA and Univ of TX Southwestern Med Ct, Dallas, TX, ⁶Rheumatology, Washington DC VAMC, Georgetown and Howard University, Washington, DC, ⁷Division of Rheumatology, Salt Lake City VA and University of Utah, Salt Lake City, UT
Background/Purpose: Cigarette smoking is a risk factor for RA and has been associated with increased disease severity and lower rates of disease remission. We examined…
Abstract Number: 2858 • 2013 ACR/ARHP Annual Meeting
Inhibition Of Chronic Pain By IL4-10 Synerkine Is Superior To IL-4 Or IL-10 Monotherapy: A Novel Strategy To Restrain Pain In Rheumatic Diseases
Niels Eijkelkamp¹, Sarita Hartgring², Cristine Steen-Louws³, Hanneke Willemen⁴, Qiu-Ling Mao-Ying⁵, Cobi Heijnen⁵, Erik Hack⁶, Annemiek Kavelaars⁵ and J.A.G. van Roon⁷, ¹Laboratory of Neuroimmunology and Developmental Origins of Disease (NIDOD), UMC Utrecht, Utrecht, Netherlands, ²Laboratory for Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ³UMC Utrecht, Utrecht, Netherlands, ⁴NIDOD, UMC Utrecht, Utrecht, Netherlands, ⁵MD Anderson Cancer Center, Houston, TX, ⁶Immunology, UMC Utrecht, Utrecht, Netherlands, ⁷Rheumatology & Clinical Immunology/Lab Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: Chronic pain is a major problem in many diseases, including RA and OA, arising from inflammation or structural damage. It is often associated with glial…
Abstract Number: 1845 • 2013 ACR/ARHP Annual Meeting
Soluble Type I Interferon Receptor 2 Is Elevated By Interferon Treatment and In Certain Autoimmune Diseases
Taher Fatakdawala¹, Michael Skawinski¹, Jonathan Ferriera², Tara Stauffer¹ and Thomas Lavoie¹, ¹Product Research & Development and Assay Services, PBL Assay Science, Piscataway, NJ, ²Quality Control, PBL Assay Science, Piscataway, NJ
Background/Purpose: The Type I Interferon (IFN) receptor is a heterodimer of chain 1 (IFNAR1) which is required for signaling, and chain 2 (IFNAR2) which binds…
Abstract Number: 934 • 2013 ACR/ARHP Annual Meeting
Interleukin-12B Is Up-Regulated By Decoy Receptor 3 In Specifically Rheumatoid Synovial Fibroblasts
Koji Fukuda¹, Yasushi Miura^1,2, Toshihisa Maeda¹, Shinya Hayashi³ and Masahiro Kurosaka³, ¹Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan, ²Department of Rehabilitation Science, Kobe University Graduate School of Health Sciences, Kobe, Japan, ³Orthopaedic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan
Background/Purpose: Decoy receptor 3 (DcR3) is a secreted decoy tumor necrosis factor receptor and competitively binds and inhibits the TNF family including Fas-ligand (FasL), LIGHT,…
Abstract Number: 2740 • 2013 ACR/ARHP Annual Meeting
High Efficacy Of Toll-Like Receptor 4 Targeting In Murine and Humanized Models Of Rheumatoid Arthritis In Comparison With IL-1 and TNF Inhibitors
Shahla Abdollahi-Roodsaz¹, Marije I. Koenders², Leo A. Joosten³, Fons A. van de Loo⁴ and Wim B. van den Berg¹, ¹Rheumatology Research and Advanced Therapeutics, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ²Rheumatology Research and Advanced Therapeutics, Radboud University Nijmegen Medical Center, Nijmegen, Netherlands, ³Department of Medicine, Radboud University Nijmegen Medical Center, Nijmegen, Netherlands, ⁴Experimental Rheumatology, Radboud university medical center, Nijmegen, Netherlands
Background/Purpose: Increased expression of Toll-like Receptor (TLR) 4 and its endogenous agonists in rheumatoid joints suggest involvement in rheumatoid arthritis (RA). The aim of this…
Abstract Number: 1824 • 2013 ACR/ARHP Annual Meeting
ONO-4059 – A Novel Small Molecule Dual Inhibitor Of Bruton’s Tyrosine Kinase (Btk) and Tec Kinase- Suppresses Osteoclastic Bone Resorption and Inflammation
Yuko Ariza¹, Toshio Yoshizawa¹, Yoshiko Ueda¹, Shingo Hotta¹, Tomoko Yasuhiro¹, Masami Narita¹, Yutaka Shichino² and Kazuhito Kawabata¹, ¹Discovery Research Laboratories 3, Ono Pharmaceutical Co., Ltd., Osaka, Japan, ²Discovery Research Laboratories, Ono Pharmaceutical Co., Ltd., Osaka, Japan
Background/Purpose: Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by leukocyte infiltration, synoviocyte hyperplasia and osteoclastogenesis, leading to erosion of the joints and cartilage,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].